Developing a case study model for successful translation of stem cell therapies.
Cell therapies derived from pluripotent stem cells are entering the preclinical and early clinical development phase, but eventual translation faces many challenges. We describe a new approach by California to form global public-private "disease team" partnerships to enable new clinical opportunities to be evaluated in the complex regulatory environment.
Trounson
Alan
A
California Institute for Regenerative Medicine, San Francisco, CA 94107, USA. atrounson@cirm.ca.gov
Baum
Elona
E
Gibbons
Don
D
Tekamp-Olson
Patricia
P
D002140:California; D064987:Cell- and Tissue-Based Therapy / Q000191:economics; D002986:Clinical Trials as Topic; D006801:Humans; D007348:Insurance, Health; D007883:Legislation, Medical; D017059:Models, Econometric; D019982:Organizational Case Studies; D039904:Pluripotent Stem Cells; D055818:Public-Private Sector Partnerships; D012109:Research Support as Topic; D057170:Translational Research, Biomedical